Nanoform Finland Oyj Stock price

Equities

NANOFH

FI4000330972

Biotechnology & Medical Research

Delayed Nasdaq Helsinki 12:17:38 2024-03-28 pm EDT 5-day change 1st Jan Change
2.71 EUR +7.11% Intraday chart for Nanoform Finland Oyj +5.04% +70.98%
Sales 2024 * 7.48M 8.07M Sales 2025 * 14.6M 15.73M Capitalization 213M 229M
Net income 2024 * -15M -16.16M Net income 2025 * -11M -11.85M EV / Sales 2024 * 24.3 x
Net cash position 2024 * 31M 33.41M Net cash position 2025 * 21.34M 22.99M EV / Sales 2025 * 13.1 x
P/E ratio 2024 *
-13.9 x
P/E ratio 2025 *
-19.4 x
Employees 165
Yield 2024 *
-
Yield 2025 *
-
Free-Float 67.95%
More Fundamentals * Assessed data
Dynamic Chart
Nanoform Finland Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nanoform Finland Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Nanoform Finland Oyj, 2023 Earnings Call, Feb 29, 2024
Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation CI
Transcript : Nanoform Finland Oyj - Special Call
Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide CI
Nanoform Finland Starts Clinical Trial for Nanocrystalline Alternative of Prostrate Cancer Drug MT
Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide CI
Transcript : Nanoform Finland Oyj, Q3 2023 Earnings Call, Nov 22, 2023
Nanoform Finland Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nanoform Finland Signs Licensing Deal for AI Technology with AstraZeneca MT
Nanoform Grant Global STARMAP[®] AI License to AstraZeneca CI
Transcript : Nanoform Finland Oyj, Q2 2023 Earnings Call, Aug 24, 2023
Nanoform Finland Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Finland’s Nanoform, Celanese to Advance Partnership in Nanoparticle-enabled Drug Delivery Study MT
More news
1 day+7.11%
1 week+5.04%
Current month-7.51%
1 month-6.87%
3 months+70.44%
6 months+53.98%
Current year+70.98%
More quotes
1 week
2.28
Extreme 2.28
2.80
1 month
2.28
Extreme 2.28
3.06
Current year
1.55
Extreme 1.55
3.50
1 year
1.47
Extreme 1.47
3.50
3 years
1.47
Extreme 1.47
8.71
5 years
1.47
Extreme 1.47
8.80
10 years
1.47
Extreme 1.47
8.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 14-12-31
Director of Finance/CFO 53 14-12-31
Investor Relations Contact - 19-04-30
Members of the board TitleAgeSince
Chairman 68 19-04-01
Director/Board Member 67 18-12-31
Director of Finance/CFO 53 14-12-31
More insiders
Date Price Change Volume
24-03-28 2.71 +7.11% 37,209
24-03-27 2.53 +5.42% 72,394
24-03-26 2.4 0.00% 121,227
24-03-25 2.4 -2.04% 48,459
24-03-22 2.45 -5.04% 28,140

Delayed Quote Nasdaq Helsinki, March 28, 2024 at 12:17 pm EDT

More quotes
Nanoform Finland Oyj is a Finland-based company that operates in the global pharmaceutical industry. The Company is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyj's business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Group's strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.71 EUR
Average target price
4.4 EUR
Spread / Average Target
+62.36%
Consensus
  1. Stock
  2. Equities
  3. Stock Nanoform Finland Oyj - Nasdaq Helsinki